• Mira Smart Conferencing
  • Home
  • Table of Contents
  • Advanced Search
 
Advanced Search

Browse All

Current Filters

CLEAR FILTER x

TITLE

Author Institution:

  • Teva Pharmaceutical Industries Ltd, Parsippany, NJ, USA, Parsippany, NJ

Filter

Partial Search: Partial searches may be entered manually by pressing enter in the filter input field.
Author Filter: Selecting one or more Authors from the Author drop down list will filter results by Author last name(s) only.

Displaying 1 - 2 of 2

  • Page:
  • 1

Treatment with Fremanezumab Attenuates the Association Between Weather and Headache in Participants with Episodic Migraine: A Post Hoc Analysis of the HALO-EM and HALO-LTS Studies

Author:Martin, Vincent   Cohen, Fred   Zhang, Ying   Zhang, Di   Peterlin, Albert   Vij, Brinder   Ortega, Mario   

Session Name:P10: Headache: Pharmacological Migraine Prevention 2  

Topic:Headache  

Program Number:P10.004  

Author Institution:Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA, Cincinnati, OH  Departments of Medicine and Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, NY  Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA, West Chester, PA  Meteorologist  Environmental Rights and Releases Exchange (ERREx) Inc., Camp Hill, PA, USA, PA  Department of Neurology and Rehabilitation Medicine, University of Cincinnati College of Medicine, OH, USA, Cincinnati, OH  Teva Pharmaceutical Industries Ltd, Parsippany, NJ, USA, Parsippany, NJ  

  • View Abstract
  • View Disclosure

Impact of Early Fremanezumab Initiation and Treatment Pauses on the Reduction of Monthly Migraine Days: Analyses from the PEARL Study

Author:Pavão Martins, Isabel   Mitsikostas, Dimos Dimitrios   Tassorelli, Cristina   Kokturk, Pinar   Zuppone, Stefania   Ortega, Mario   Bryson, Juline   Ramirez Campos, Verena   

Session Name:P10: Headache: Pharmacological Migraine Prevention 2  

Topic:Headache  

Program Number:P10.007  

Author Institution:Centro de Estudos Egas Moniz, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, Portugal  Department of First Neurology, Aeginition Hospital, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece  Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy  IRCCS C. Mondino Foundation, Pavia, Italy, Italy  Teva Netherlands B.V., Haarlem, The Netherlands, Netherlands  Teva Pharmaceutical Industries Ltd, Parsippany, NJ, USA, Parsippany, NJ  Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA, West Chester, PA  Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA, PA  

  • View Abstract
  • View Disclosure

Displaying 1 - 2 of 2

  • Page:
  • 1

© 2015 Mira Smart Conference | http://www.mirasmart.com